Skip to main content
Industry News
Groups apply COVID-19 vaccine model to cancer research

Getting a new drug or vaccine from the lab to the patient's bedside can take a decade or more, but through public-private partnerships and international collaboration, it took less than a year from the time the SARS-CoV-2 genome was sequenced to get more than one COVID-19 vaccine approved, writes Ethan Dmitrovsky, director of the Frederick National Laboratory for Cancer Research. The National Cancer Institute's Chemical Biology Consortium, the Innovative Medicines Initiative in Europe and Open Targets are applying the same model to cancer therapies and, coupled with real-world data, could accelerate progress, Dmitrovsky writes.

Full Story: